Overview of safety of non-biologic and biologic DMARDs
Safety data come from a number of sources. Randomized clinical trials tend to be relatively short, exclude patients with significant comorbidity, have limited numbers of subjects and are primarily powered for efficacy. The most useful post-marketing data come from large national registries, such as...
Saved in:
| Published in | Rheumatology (Oxford, England) Vol. 51; no. suppl 6; pp. vi37 - vi43 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | English |
| Published |
England
01.12.2012
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Safety data come from a number of sources. Randomized clinical trials tend to be relatively short, exclude patients with significant comorbidity, have limited numbers of subjects and are primarily powered for efficacy. The most useful post-marketing data come from large national registries, such as Britain's BSRBR, Sweden's ARTIS, Germany's RABBIT, France's DANBIO, Spain's BIODASER and North America's CORRONA. Among the most commonly used non-biologic DMARDs, MTX is associated with risks of hepatotoxicity and cytopenia, as well as pneumonitis, particularly during the first year of treatment. Regarding TNF inhibitors, there is an increased risk of infection (including serious infections) by bacterial pathogens, atypical fungi and opportunistic pathogens. When possible, pneumococcal and influenza vaccines should be given before initiation of treatment with any biologic DMARD. Screening for latent tuberculosis is recommended for all TNF inhibitors, and has been shown to reduce the risk of reactivation. Evidence from registries suggests that there is no increased risk of solid tumours with TNF inhibitor treatment; however, non-melanoma skin cancers are more common. Specific risks with other biologic DMARDs include gastrointestinal perforation with tocilizumab, progressive multifocal leucoencephalopathy with rituximab and pulmonary infections with abatacept. Overall, the safety of biologic and non-biologic DMARDs appears to be reasonable, particularly compared with the risks associated with the disease itself. |
|---|---|
| AbstractList | Safety data come from a number of sources. Randomized clinical trials tend to be relatively short, exclude patients with significant comorbidity, have limited numbers of subjects and are primarily powered for efficacy. The most useful post-marketing data come from large national registries, such as Britain's BSRBR, Sweden's ARTIS, Germany's RABBIT, France's DANBIO, Spain's BIODASER and North America's CORRONA. Among the most commonly used non-biologic DMARDs, MTX is associated with risks of hepatotoxicity and cytopenia, as well as pneumonitis, particularly during the first year of treatment. Regarding TNF inhibitors, there is an increased risk of infection (including serious infections) by bacterial pathogens, atypical fungi and opportunistic pathogens. When possible, pneumococcal and influenza vaccines should be given before initiation of treatment with any biologic DMARD. Screening for latent tuberculosis is recommended for all TNF inhibitors, and has been shown to reduce the risk of reactivation. Evidence from registries suggests that there is no increased risk of solid tumours with TNF inhibitor treatment; however, non-melanoma skin cancers are more common. Specific risks with other biologic DMARDs include gastrointestinal perforation with tocilizumab, progressive multifocal leucoencephalopathy with rituximab and pulmonary infections with abatacept. Overall, the safety of biologic and non-biologic DMARDs appears to be reasonable, particularly compared with the risks associated with the disease itself. Safety data come from a number of sources. Randomized clinical trials tend to be relatively short, exclude patients with significant comorbidity, have limited numbers of subjects and are primarily powered for efficacy. The most useful post-marketing data come from large national registries, such as Britain's BSRBR, Sweden's ARTIS, Germany's RABBIT, France's DANBIO, Spain's BIODASER and North America's CORRONA. Among the most commonly used non-biologic DMARDs, MTX is associated with risks of hepatotoxicity and cytopenia, as well as pneumonitis, particularly during the first year of treatment. Regarding TNF inhibitors, there is an increased risk of infection (including serious infections) by bacterial pathogens, atypical fungi and opportunistic pathogens. When possible, pneumococcal and influenza vaccines should be given before initiation of treatment with any biologic DMARD. Screening for latent tuberculosis is recommended for all TNF inhibitors, and has been shown to reduce the risk of reactivation. Evidence from registries suggests that there is no increased risk of solid tumours with TNF inhibitor treatment; however, non-melanoma skin cancers are more common. Specific risks with other biologic DMARDs include gastrointestinal perforation with tocilizumab, progressive multifocal leucoencephalopathy with rituximab and pulmonary infections with abatacept. Overall, the safety of biologic and non-biologic DMARDs appears to be reasonable, particularly compared with the risks associated with the disease itself.Safety data come from a number of sources. Randomized clinical trials tend to be relatively short, exclude patients with significant comorbidity, have limited numbers of subjects and are primarily powered for efficacy. The most useful post-marketing data come from large national registries, such as Britain's BSRBR, Sweden's ARTIS, Germany's RABBIT, France's DANBIO, Spain's BIODASER and North America's CORRONA. Among the most commonly used non-biologic DMARDs, MTX is associated with risks of hepatotoxicity and cytopenia, as well as pneumonitis, particularly during the first year of treatment. Regarding TNF inhibitors, there is an increased risk of infection (including serious infections) by bacterial pathogens, atypical fungi and opportunistic pathogens. When possible, pneumococcal and influenza vaccines should be given before initiation of treatment with any biologic DMARD. Screening for latent tuberculosis is recommended for all TNF inhibitors, and has been shown to reduce the risk of reactivation. Evidence from registries suggests that there is no increased risk of solid tumours with TNF inhibitor treatment; however, non-melanoma skin cancers are more common. Specific risks with other biologic DMARDs include gastrointestinal perforation with tocilizumab, progressive multifocal leucoencephalopathy with rituximab and pulmonary infections with abatacept. Overall, the safety of biologic and non-biologic DMARDs appears to be reasonable, particularly compared with the risks associated with the disease itself. |
| Author | Ruderman, E. M. |
| Author_xml | – sequence: 1 givenname: E. M. surname: Ruderman fullname: Ruderman, E. M. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23221586$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkFtLw0AQhRep2Iv-AkHy6EvsZm_ZPJbWG1QKos9hs5nVaJKtu0ml_96E1iI-6NOcYb4zw5wxGtS2BoTOI3wV4YRO3Su0lWpsaV-203fwRNIjNIqYICGmlAwOmrAhGnv_hjHmEZUnaEgoIRGXYoTEagNuU8BnYE3glYFm26vuVJgV_epCB6rOg0OzeJg9LvwpOjaq9HC2rxP0fHP9NL8Ll6vb-_lsGWoqaBNCrhIucqwS4EQAY9pkUisiNdc8JhIM8ERlNDNY6W7ABc5EwowCEQNhmk7Q5W7v2tmPFnyTVoXXUJaqBtv6tPuQ8YjEcfw_ShiWiYxwj17s0TarIE_XrqiU26bfsXQA3QHaWe8dmAMS4bQPP_0ZfroLv3Mlv1y6aFRT2Lpxqij_9H4BoC6QJQ |
| CitedBy_id | crossref_primary_10_1517_14740338_2015_993605 crossref_primary_10_1111_ddg_13200_g crossref_primary_10_1155_2022_4787643 crossref_primary_10_2478_prolas_2023_0003 crossref_primary_10_1093_ibd_izy076 crossref_primary_10_1007_s00296_021_04849_9 crossref_primary_10_1007_s10067_016_3359_x crossref_primary_10_1111_1756_185X_12659 crossref_primary_10_1136_bmjopen_2016_011916 crossref_primary_10_1016_j_semarthrit_2015_10_001 crossref_primary_10_1007_s40259_013_0022_9 crossref_primary_10_1155_2017_7915340 crossref_primary_10_3389_fphar_2022_999017 crossref_primary_10_1016_j_rhum_2013_11_008 crossref_primary_10_1007_s10792_015_0136_9 crossref_primary_10_1016_j_semarthrit_2019_01_009 crossref_primary_10_1002_acr_22424 crossref_primary_10_1186_s41927_020_00158_z crossref_primary_10_1007_s40259_016_0197_y crossref_primary_10_1016_j_cyto_2022_155978 crossref_primary_10_1517_14740338_2014_857655 crossref_primary_10_1002_art_39399 crossref_primary_10_1093_rheumatology_kead158 crossref_primary_10_33878_2073_7556_2018_0_3_94_102 crossref_primary_10_1111_jphp_13231 crossref_primary_10_1007_s40265_014_0239_z crossref_primary_10_2174_1573397114666181119121519 crossref_primary_10_1002_art_40187 crossref_primary_10_1016_j_trsl_2014_09_006 crossref_primary_10_1007_s40265_017_0829_7 crossref_primary_10_1093_rheumatology_keu040 crossref_primary_10_1007_s12272_014_0337_1 crossref_primary_10_1080_24725625_2019_1702493 crossref_primary_10_1371_journal_pone_0179179 crossref_primary_10_1007_s13555_023_00905_3 crossref_primary_10_1016_j_pec_2015_12_001 crossref_primary_10_1177_1715163514521377 crossref_primary_10_1016_j_autrev_2020_102528 crossref_primary_10_1016_j_jbspin_2013_11_001 crossref_primary_10_7759_cureus_69401 crossref_primary_10_1007_s15010_016_0884_0 crossref_primary_10_1111_ddg_13200 crossref_primary_10_3389_fphar_2021_609148 crossref_primary_10_1002_acr_23824 crossref_primary_10_1186_s12348_016_0107_y crossref_primary_10_1002_acr_23426 crossref_primary_10_1177_0036933018763277 crossref_primary_10_1016_j_intimp_2022_108853 crossref_primary_10_1016_j_jcjq_2018_12_003 crossref_primary_10_1111_cei_12252 crossref_primary_10_1016_j_jfo_2017_11_012 crossref_primary_10_1093_rheumatology_keu032 crossref_primary_10_4049_jimmunol_1301611 crossref_primary_10_20935_AcadBiol6147 crossref_primary_10_1111_bcp_13192 crossref_primary_10_13005_bbra_2536 crossref_primary_10_1111_bph_15095 crossref_primary_10_1016_j_rdc_2013_05_004 crossref_primary_10_1111_apt_13140 crossref_primary_10_2217_imt_2018_0113 crossref_primary_10_1002_pds_4332 crossref_primary_10_1016_j_phytol_2019_09_011 crossref_primary_10_1007_s00347_013_3016_6 crossref_primary_10_1111_imm_12142 crossref_primary_10_1002_acr_23738 crossref_primary_10_4161_19420862_2014_985547 crossref_primary_10_1186_s41927_020_00145_4 crossref_primary_10_1093_ajhp_zxab257 crossref_primary_10_1016_j_rbr_2014_06_006 crossref_primary_10_1007_s12325_020_01437_4 crossref_primary_10_1517_13543784_2014_950837 crossref_primary_10_1007_s40259_013_0076_8 crossref_primary_10_1007_s40265_014_0258_9 crossref_primary_10_4142_jvs_22069 crossref_primary_10_1177_1756284819848631 crossref_primary_10_1007_s00393_013_1160_7 crossref_primary_10_1111_1756_185X_12264 crossref_primary_10_3346_jkms_2018_33_e168 crossref_primary_10_53941_ijddp_2024_100018 crossref_primary_10_1097_MJT_0000000000001455 crossref_primary_10_1136_rmdopen_2016_000352 crossref_primary_10_1080_14728222_2023_2285784 crossref_primary_10_1016_j_rhum_2017_01_003 crossref_primary_10_3390_cells11081309 crossref_primary_10_1016_j_jbspin_2016_02_028 |
| Cites_doi | 10.1136/ard.2007.083188 10.1002/art.22056 10.1136/ard.2010.128637 10.1136/ard.2009.125658 10.1182/blood-2008-10-186999 10.1136/ard.2006.062760 10.1002/art.24632 10.7326/0003-4819-137-9-200211050-00007 10.1056/NEJMoa011110 10.1136/ard.2008.089276 10.1136/ard.2005.035287 10.1002/art.10529 10.1002/art.21043 10.1016/j.semarthrit.2007.10.011 10.1002/art.22070 10.1002/acr.20129 10.1016/j.amjcard.2011.06.054 10.3201/eid1510.090310 10.1136/ard.53.4.224 10.1136/ard.2007.085852 10.1002/art.21568 10.1093/rheumatology/ker113 10.1002/art.22750 10.1002/art.23721 10.1136/ard.2010.149419 10.1002/art.23059 10.1002/art.27555 10.1001/jama.2009.146 10.1136/ard.2008.097527 10.1002/art.25034 10.1002/art.22809 10.1093/rheumatology/keq232 10.1136/ard.2009.120626 10.1093/rheumatology/keq242 10.1007/s10067-008-1007-9 10.1161/01.CIR.0000077913.60364.D2 10.1016/j.ophtha.2010.11.017 10.1002/art.11137 10.1002/art.21675 10.1097/MPG.0b013e3181957a11 10.1002/art.10524 10.1136/ard.2008.101378 10.7326/0003-4819-127-5-199709010-00003 10.1093/rheumatology/kel216a 10.1001/jama.295.19.2275 10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W 10.2165/00044011-200626020-00001 |
| ContentType | Journal Article |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 M7N |
| DOI | 10.1093/rheumatology/kes283 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Algology Mycology and Protozoology Abstracts (Microbiology C) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Algology Mycology and Protozoology Abstracts (Microbiology C) |
| DatabaseTitleList | MEDLINE Algology Mycology and Protozoology Abstracts (Microbiology C) MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1462-0332 |
| EndPage | vi43 |
| ExternalDocumentID | 23221586 10_1093_rheumatology_kes283 |
| Genre | Journal Article Review |
| GroupedDBID | --- -E4 .2P .I3 .XZ .ZR 08P 0R~ 18M 1TH 29P 2WC 354 4.4 48X 53G 5RE 5VS 5WA 5WD 70D AABZA AACZT AAJKP AAJQQ AAMDB AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAWTL AAYXX ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPTD ABQLI ABQNK ABVGC ABXVV ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AGINJ AGKEF AGORE AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CITATION CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBD EBS EE~ EJD EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IOX J21 JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z MHKGH N9A NGC NOMLY NOYVH NU- NVLIB O0~ O9- OAUYM OAWHX OBH OCZFY ODMLO OHH OJQWA OJZSN OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 ROL ROX RUSNO RW1 RXO SV3 TCURE TEORI TJX TR2 VVN W8F WOQ X7H YAYTL YKOAZ YXANX ZKX ZY1 ~91 .GJ 3O- AAGKA AAPGJ AAWDT ABNGD ACFRR ACUKT ADMTO AEHUL AFFNX AGQPQ AHGBF AQDSO ATTQO AZFZN CAG CGR COF CUY CVF ECM EIF EIHJH FEDTE HVGLF NPM NTWIH O~Y PB- RIG RNI RZF RZO TMA ZGI 7X8 M7N |
| ID | FETCH-LOGICAL-c363t-eda956d0a9e526e44cfb8ca28c5c5728efe59ab3bf0ac8ca560b694fae67e24c3 |
| ISSN | 1462-0324 1462-0332 |
| IngestDate | Fri Jul 11 02:16:07 EDT 2025 Fri Jul 11 06:45:00 EDT 2025 Mon Jul 21 05:56:38 EDT 2025 Tue Jul 01 01:36:27 EDT 2025 Thu Apr 24 23:00:23 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | suppl 6 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c363t-eda956d0a9e526e44cfb8ca28c5c5728efe59ab3bf0ac8ca560b694fae67e24c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| PMID | 23221586 |
| PQID | 1240898107 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1464512777 proquest_miscellaneous_1240898107 pubmed_primary_23221586 crossref_primary_10_1093_rheumatology_kes283 crossref_citationtrail_10_1093_rheumatology_kes283 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2012-12-01 |
| PublicationDateYYYYMMDD | 2012-12-01 |
| PublicationDate_xml | – month: 12 year: 2012 text: 2012-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Rheumatology (Oxford, England) |
| PublicationTitleAlternate | Rheumatology (Oxford) |
| PublicationYear | 2012 |
| References | van der Veen (7_15511066) 1994; 53 Bingham (14_36381036) 2010; 62 Setoguchi (33_22564209) 2006; 54 (6_44306822) 2011; 31 (16_40695066) 2011; 2 (37_40441536) 2011; 70 Mohan (40_11435240) 2001; 44 (8_34547585) 2010; 69 Strangfeld (29_34012639) 2009; 301 Bongartz (15_22087310) 2006; 295 Carmona (25_19085630) 2005; 52 G mez-Reino (24_17755954) 2003; 48 Baecklund (32_21686468) 2006; 54 (34_31045132) 2009; 68 Fuchs (27_31937468) 2009; 28 Doran (1_17260547) 2002; 46 (55_37669097) 2011; 50 (11_33360241) 2010; 69 (19_39135206) 2011; 70 Tilling (4_23126422) 2006; 26 Jacobsson (52_18961998) 2005; 32 (47_32752776) 2009; 68 (21_20978897) 2006; 65 (3_22546915) 2008; 47 Keystone (48_29956016) 2007; 56 Bigbee (46_29172687) 2007; 56 (49_34207788) 2009; 113 Alarcon (5_5706179) 1997; 127 (54_37208526) 2010; 69 Saag (2_31234049) 2008; 59 (17_37774943) 2011; 50 (30_37446559) 2010; 69 (18_23574086) 2007; 66 (39_17699665) 2003; 107 Dixon (51_29340946) 2007; 56 Marmor (13_39157720) 2011; 118 Mackey (35_34257265) 2009; 48 Wolfe (20_21546829) 2006; 54 (42_30288145) 2009; 68 Weinblatt (45_22564092) 2006; 54 Keane (22_11334628) 2001; 345 (43_44306823) 2011; 22 Carroll (31_32727155) 2008; 38 (38_39477539) 2011; 50 Kremer (12_17316171) 2002; 137 (36_40283373) 2010; 62 Winthrop (28_35880645) 2009; 15 Micha (53_40621107) 2011; 108 Tubach (23_35216834) 2009; 60 Gottenberg (50_37371812) 2010; 62 (10_32847400) 2003; 1 (41_44306819) 2009; 68 Doran (9_17260548) 2002; 46 |
| References_xml | – volume: 68 start-page: 25 issn: 0003-4967 issue: 1 year: 2009 ident: 42_30288145 publication-title: Annals of the Rheumatic Diseases doi: 10.1136/ard.2007.083188 – volume: 54 start-page: 2757 issn: 0004-3591 issue: 9 year: 2006 ident: 33_22564209 publication-title: Arthritis and rheumatism doi: 10.1002/art.22056 – volume: 22 start-page: 122 issn: 1439-7595 year: 2011 ident: 43_44306823 – volume: 70 start-page: 785 issn: 0003-4967 issue: 5 year: 2011 ident: 19_39135206 publication-title: Annals of the Rheumatic Diseases doi: 10.1136/ard.2010.128637 – volume: 69 start-page: 1751 issn: 0003-4967 issue: 10 year: 2010 ident: 30_37446559 publication-title: Annals of the Rheumatic Diseases doi: 10.1136/ard.2009.125658 – volume: 113 start-page: 4834 issn: 0006-4971 issue: 20 year: 2009 ident: 49_34207788 publication-title: Blood doi: 10.1182/blood-2008-10-186999 – volume: 66 start-page: 1339 issn: 0003-4967 issue: 10 year: 2007 ident: 18_23574086 publication-title: Annals of the Rheumatic Diseases doi: 10.1136/ard.2006.062760 – volume: 60 start-page: 1884 issn: 0004-3591 issue: 7 year: 2009 ident: 23_35216834 publication-title: Arthritis and rheumatism doi: 10.1002/art.24632 – volume: 137 start-page: 726 issn: 0003-4819 issue: 9 year: 2002 ident: 12_17316171 publication-title: Annals of Internal Medicine doi: 10.7326/0003-4819-137-9-200211050-00007 – volume: 345 start-page: 1098 issn: 0028-4793 issue: 15 year: 2001 ident: 22_11334628 publication-title: New England Journal of Medicine doi: 10.1056/NEJMoa011110 – volume: 69 start-page: 380 issn: 0003-4967 issue: 2 year: 2010 ident: 8_34547585 publication-title: Annals of the Rheumatic Diseases doi: 10.1136/ard.2008.089276 – volume: 65 start-page: 379 issn: 0003-4967 issue: 3 year: 2006 ident: 21_20978897 publication-title: Annals of the Rheumatic Diseases doi: 10.1136/ard.2005.035287 – volume: 46 start-page: 2294 issn: 0004-3591 issue: 9 year: 2002 ident: 9_17260548 publication-title: Arthritis and rheumatism doi: 10.1002/art.10529 – volume: 52 start-page: 1766 issn: 0004-3591 issue: 6 year: 2005 ident: 25_19085630 publication-title: Arthritis and rheumatism doi: 10.1002/art.21043 – volume: 38 start-page: 208 issn: 0049-0172 issue: 3 year: 2008 ident: 31_32727155 publication-title: Seminars in arthritis and rheumatism doi: 10.1016/j.semarthrit.2007.10.011 – volume: 54 start-page: 2807 issn: 0004-3591 issue: 9 year: 2006 ident: 45_22564092 publication-title: Arthritis and rheumatism doi: 10.1002/art.22070 – volume: 62 start-page: 755 issn: 0893-7524 year: 2010 ident: 36_40283373 publication-title: Arthritis care and research : the official journal of the Arthritis Health Professions Association doi: 10.1002/acr.20129 – volume: 108 start-page: 1362 issn: 0002-9149 issue: 9 year: 2011 ident: 53_40621107 publication-title: The American journal of cardiology doi: 10.1016/j.amjcard.2011.06.054 – volume: 15 start-page: 1556 issn: 1080-6040 issue: 10 year: 2009 ident: 28_35880645 publication-title: Emerging infectious diseases doi: 10.3201/eid1510.090310 – volume: 53 start-page: 224 issn: 0003-4967 issue: 4 year: 1994 ident: 7_15511066 publication-title: Annals of the Rheumatic Diseases doi: 10.1136/ard.53.4.224 – volume: 68 start-page: 648 issn: 0003-4967 issue: 5 year: 2009 ident: 34_31045132 publication-title: Annals of the Rheumatic Diseases doi: 10.1136/ard.2007.085852 – volume: 54 start-page: 628 issn: 0004-3591 issue: 2 year: 2006 ident: 20_21546829 publication-title: Arthritis and rheumatism doi: 10.1002/art.21568 – volume: 50 start-page: 1431 issn: 0080-2727 issue: 8 year: 2011 ident: 38_39477539 publication-title: Rheumatology doi: 10.1093/rheumatology/ker113 – volume: 56 start-page: 2557 issn: 0004-3591 issue: 8 year: 2007 ident: 46_29172687 publication-title: Arthritis and rheumatism doi: 10.1002/art.22750 – volume: 59 start-page: 762 issn: 0004-3591 issue: 6 year: 2008 ident: 2_31234049 publication-title: Arthritis and rheumatism doi: 10.1002/art.23721 – volume: 2 start-page: CD008794 issn: 1469-493X year: 2011 ident: 16_40695066 publication-title: Cochrane database of systematic reviews (Online) – volume: 70 start-page: 1895 issn: 0003-4967 issue: 11 year: 2011 ident: 37_40441536 publication-title: Annals of the Rheumatic Diseases doi: 10.1136/ard.2010.149419 – volume: 56 start-page: 3896 issn: 0004-3591 issue: 12 year: 2007 ident: 48_29956016 publication-title: Arthritis and rheumatism doi: 10.1002/art.23059 – volume: 62 start-page: 2625 issn: 0004-3591 issue: 9 year: 2010 ident: 50_37371812 publication-title: Arthritis and rheumatism doi: 10.1002/art.27555 – volume: 1 start-page: CD002047 issn: 1469-493X year: 2003 ident: 10_32847400 publication-title: Cochrane database of systematic reviews (Online) – volume: 301 start-page: 737 issn: 0098-7484 issue: 7 year: 2009 ident: 29_34012639 publication-title: JAMA doi: 10.1001/jama.2009.146 – volume: 68 start-page: 797 year: 2009 ident: 41_44306819 publication-title: A RANDOMISED CONTROLLED TRIAL ANN RHEUM DIS – volume: 68 start-page: 1819 issn: 0003-4967 issue: 12 year: 2009 ident: 47_32752776 publication-title: Annals of the Rheumatic Diseases doi: 10.1136/ard.2008.097527 – volume: 32 start-page: 1213 issn: 0315-162X issue: 7 year: 2005 ident: 52_18961998 publication-title: The Journal of Rheumatology – volume: 31 start-page: 79 issn: 0770-3198 year: 2011 ident: 6_44306822 publication-title: Clinical rheumatology – volume: 62 start-page: 64 issn: 0004-3591 issue: 1 year: 2010 ident: 14_36381036 publication-title: Arthritis and rheumatism doi: 10.1002/art.25034 – volume: 56 start-page: 2905 issn: 0004-3591 issue: 9 year: 2007 ident: 51_29340946 publication-title: Arthritis and rheumatism doi: 10.1002/art.22809 – volume: 50 start-page: 101 issn: 0080-2727 issue: 1 year: 2011 ident: 55_37669097 publication-title: Rheumatology doi: 10.1093/rheumatology/keq232 – volume: 69 start-page: 1086 issn: 0003-4967 issue: 6 year: 2010 ident: 54_37208526 publication-title: Annals of the Rheumatic Diseases doi: 10.1136/ard.2009.120626 – volume: 50 start-page: 124 issn: 0080-2727 issue: 1 year: 2011 ident: 17_37774943 publication-title: Rheumatology doi: 10.1093/rheumatology/keq242 – volume: 28 start-page: 167 issn: 0770-3198 issue: 2 year: 2009 ident: 27_31937468 publication-title: Clinical rheumatology doi: 10.1007/s10067-008-1007-9 – volume: 107 start-page: 3133 issn: 0009-7322 issue: 25 year: 2003 ident: 39_17699665 publication-title: Circulation doi: 10.1161/01.CIR.0000077913.60364.D2 – volume: 118 start-page: 415 issn: 0161-6420 issue: 2 year: 2011 ident: 13_39157720 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2010.11.017 – volume: 48 start-page: 2122 issn: 0004-3591 issue: 8 year: 2003 ident: 24_17755954 publication-title: Arthritis and rheumatism doi: 10.1002/art.11137 – volume: 54 start-page: 692 issn: 0004-3591 issue: 3 year: 2006 ident: 32_21686468 publication-title: Arthritis and rheumatism doi: 10.1002/art.21675 – volume: 48 start-page: 386 issn: 0277-2116 issue: 3 year: 2009 ident: 35_34257265 publication-title: Journal of pediatric gastroenterology and nutrition doi: 10.1097/MPG.0b013e3181957a11 – volume: 46 start-page: 2287 issn: 0004-3591 issue: 9 year: 2002 ident: 1_17260547 publication-title: Arthritis and rheumatism doi: 10.1002/art.10524 – volume: 69 start-page: 43 issn: 0003-4967 issue: 01 year: 2010 ident: 11_33360241 publication-title: Annals of the Rheumatic Diseases doi: 10.1136/ard.2008.101378 – volume: 127 start-page: 356 issn: 0003-4819 issue: 5 year: 1997 ident: 5_5706179 publication-title: Annals of Internal Medicine doi: 10.7326/0003-4819-127-5-199709010-00003 – volume: 47 start-page: 924 issn: 0080-2727 issue: 6 year: 2008 ident: 3_22546915 publication-title: Rheumatology doi: 10.1093/rheumatology/kel216a – volume: 295 start-page: 2275 issn: 0098-7484 issue: 19 year: 2006 ident: 15_22087310 publication-title: JAMA doi: 10.1001/jama.295.19.2275 – volume: 44 start-page: 2862 issn: 0004-3591 issue: 12 year: 2001 ident: 40_11435240 publication-title: Arthritis and rheumatism doi: 10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W – volume: 26 start-page: 55 issn: 1173-2563 issue: 2 year: 2006 ident: 4_23126422 doi: 10.2165/00044011-200626020-00001 |
| SSID | ssj0005138 |
| Score | 2.4271994 |
| SecondaryResourceType | review_article |
| Snippet | Safety data come from a number of sources. Randomized clinical trials tend to be relatively short, exclude patients with significant comorbidity, have limited... |
| SourceID | proquest pubmed crossref |
| SourceType | Aggregation Database Index Database Enrichment Source |
| StartPage | vi37 |
| SubjectTerms | Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Biological Products - adverse effects Biological Products - therapeutic use Clinical trials Humans Mycobacterium Opportunistic Infections - epidemiology Registries Risk Factors Treatment Outcome |
| Title | Overview of safety of non-biologic and biologic DMARDs |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/23221586 https://www.proquest.com/docview/1240898107 https://www.proquest.com/docview/1464512777 |
| Volume | 51 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fS-QwEA6ewnEvcuf9UO9OKvjm9WyTNJs-yqmIuArLLuxbSdIJJ8oq7q6If_1NmrRGTkVloTRptin5urNfkplvCNnKtNQ6K9yeoUthxmyZStUzqdRG1TnkhjIXKNw_EYcjfjQuxvc5PZvokpn-be4ejSt5C6pYh7i6KNlXINvdFCvwHPHFIyKMxxdhfHrjfuk-8mSqLHjvCpzQp15bKWixdoW9_u5gbxrz0cFfmCNn9UJMTnn0tnV2D9k9opWCwbx2ZnzSms-wkBqWDHIauV94K8cFVrCwsAiP1AXTWOTbTXLR7djG3Zx5mZb_jK8XprqOHhyL5zClPlXNQ7Hrk9PqYHR8XA33x8N3ZIkiy29itceRh07eJCLvnqwVjSrZTtzJju_iIbF4YrbQsIbhR7Ic6H6y67H7RBZgskLe94NDw2ciWgiTS5t4CN1ZDGGCKCRdwUP4hYwO9od_DtOQyiI1TLBZCrXCiWidqRIKKoBzY7U0ikpTmKJHJVgoSqWZtpkyeAF5qBYltwpEDyg37CtZxK5hlSRaYEv8cIszaa7wv5a5XHGMWy6tqGGN0HYcKhN03l26kYvK-xuwKh68yg_eGvnVfenKy5w833yzHeAKzZHbY1ITuJxPq9xJ5pUyz3rPtHG76Tkijm2-eXS6TpHgIwmVYv0FPXwnH-7f7h9kcXY9h59IEWd6o3mR_gEqiGuO |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Overview+of+safety+of+non-biologic+and+biologic+DMARDs&rft.jtitle=Rheumatology+%28Oxford%2C+England%29&rft.au=Ruderman%2C+Eric+M&rft.date=2012-12-01&rft.issn=1462-0332&rft.eissn=1462-0332&rft.volume=51+Suppl+6&rft.spage=vi37&rft_id=info:doi/10.1093%2Frheumatology%2Fkes283&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-0324&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-0324&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-0324&client=summon |